x 

0 Activities
0 Activities
    • No Saved Activities

Pulmonary Hypertension (PH/PAH)

  2. Home
  3. Education
  4. Top Disease Areas
  5. Pulmonary Hypertension (PH/PAH)
  6. Specialty Area
  7. Internal Medicine
Page 4 of 4
Results 226 - 293 of 293
9916-scholand
New Tools to Improve the Diagnosis of IPF vs Other ILDs
9916-brown
New Research on Therapies for Patients with Pulmonary Fibrosis
9916-richeldi
The SENSCIS Trial: Exciting News for Scleroderma-Associated ILD
9916-cc-cme
2019 Summer Pulmonary Updates: The Experts Weigh In
sma-journal-icon_263x0
Gene Therapy for SMA: An Emerging Treatment Option for a Devastating Disease
med-doc-aatd
A Closer Look at Alpha-1 Antitrypsin Deficiency: Peggy’s Story
med-doc-ph
How Pulmonary Arterial Hypertension Has Changed Iain’s Life
9834-0002
SMA: Data, Insights and Practice
9829-0001
From Bench to Bedside: Gene Therapy Approaches for Rare Diseases
hopa-icon8
Biosimilars: Applying the Science to Hematology/Oncology Practice
9816-0001
The Latest from a Recent Pulmonary Conference in San Antonio
9816-0010
Updates in Inoperable CTEPH
9816-0009
The Importance of Early Integration of Palliative Care
9816-0006
Management of IPF Patients in 2018
9816-0005
Updates in the Diagnosis of ILD and the Role of Cryobiopsy
9816-00045
Overview of the Latest Clinical Trials in IPF
9816-0003
Evolution of Antifibrotic Therapy in IPF
9816-0002
Take Home Messages from the 2018 CHEST Annual Meeting
9816-0008
What We’re Learning from the IPF-PRO Registry
9816-0007
Comparing the 2017 Fleischner Society Guidelines and the 2018 ATS Guidelines
9808-0004
What’s New in Spinal Muscular Atrophy? Reporting from Dallas
atopic-derm4
Atopic Dermatitis: Putting it Together (Dermatology)
atopic-derm3
Atopic Dermatitis: Putting it Together (Primary Care)
atopic-derm2 copy
Atopic Dermatitis: Recent and Emerging Therapies
atopic-derm1
An Introduction to Atopic Dermatitis
9808-0003
SMA Updates from Los Angeles
pah icon
PAH Today: Mastering Current, Tailored Treatment
No image set
Achieving Better Control of Severe Asthma
asthma-uncontrol icon
A Personalized Approach to Managing Uncontrolled Asthma
9808-0002
Updates in SMA and Gene Therapy from Arlington, VA
Proper_Use_of_an_Inhaler_264x150
Proper Use of an Inhaler
psoriasis-nurse
Psoriasis Management Considerations: What Would You Do?
psoriasis-case3
Jamie Develops Complications with Her Psoriasis
psoriasis-case2
Psoriasis: Three Case Studies in the Primary Care Setting
psoriasis-case1
Cindy Has a Complex Case of Psoriasis
9707-ella
Famous People with Diabetes: Ella Fitzgerald
9707-jerry
Famous People with Diabetes: Jerry Garcia
aims icon-target
Targeting B-cells in Primary Progressive MS (PPMS)
aims icon-comorb
Comorbidities and Selection of DMTs
aims icon-gut
The Gut Microbiota in MS
aims icon-early
Early MS: Induction Therapy and Escalation Strategies
aims icon-vitamin
Vitamin D: Modifiable Risk Factor and its Role in the Management of Patients with MS
t2diabetes-slides1
Download Slides: Optimizing Diabetes Treatment in a Sea of Treatment Options
t2diabetes-slides2
Download Slides: Advancing T2DM Therapy with Confidence
t2diabetes-louise
Getting to Goal Can Be Difficult: Louise
t2diabetes-brian
Getting to Goal Can Be Difficult: Brian
IL-rheum-case3
Considering Biosimilars in Patients Failing their Initial Biologic
IL-rheum-case2
When to Switch? Biologically Experienced Patients with Spondyloarthritis
IL-rheum-case1
Innovator or Biosimilar for a Patient with Rheumatoid Arthritis
IL-gastro-case3
Ulcerative Colitis: What Can You Expect When a Patient is Switched to a Biosimilar?
IL-gastro-case2
Biosimilars in Patients with Crohn’s Disease Failing an Initial Biologic
IL-gastro-case1
Innovator or Biosimilar for a Patient with Ulcerative Colitis?
IL-derm-case3
Switching Between Biologics: Is a Biosimilar an Option?
IL-derm-case2
When to Switch? Biologically Experienced Psoriasis Patients
IL-derm-case1
Innovator or Biosimilar for a Patient with Psoriasis
IL-fund-case4
Interchangeability and Pharmacy-Level Substitution
IL-fund-case3
FDA Criteria: Biosimilar Approval, Manufacturing, & Naming
IL-fund-case2
What is the Difference Between a Biosimilar and a Generic?
biosims-full
Sorting it Out: Biologics, Biosimilars, Small Molecule Drugs, and Generics
biosims-green5
Are You Ready to Use Biosimilars in Your Practice?
biosims-full3
Health Care Providers’ Perspectives on Biosimilars: Based in Fact or Not?
biosims-green3
Pharmacovigilance and Biosimilars: Any Special Considerations?
biosims-full5
Interchangeability and Biosimilars: What will this Mean for Clinical Practice?
biosims-green8
Can a Biosimilar be Used for the Same Indications Approved for the Reference Biologic?
biosims-full7
Biosimilars: As Safe and Effective as the Reference Product?
biosims-green
Drift and the Manufacturing of Biologics: What is it and Does it Matter?
biosims-full8
Biosimilars in Clinical Practice: Interchangeability and Extrapolation
No image set
Addressing Common Barriers to Adherence
Page 4 of 4

Search